Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 11, 2009, Pages 1151-1158

  Zhang, Tianyu ^a   Zhang, Ming ^a   Rosenthal, Ian M ^a,b   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

BCG; Isoniazid; Mouse; Pyrazinamide; Rifampin

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RECOMBINANT VACCINE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 72749096722     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200905-0795OC     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention and American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49:1-51.
2. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R, Raviglione MC, World Health Organization. European framework for tuberculosis control and elimination in countries with a low incidence: recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002;19:765-775.
3. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-973.
4. Public Health Agency of Canada and Canadian Lung Association/Canadian Thoracic Association. Canadian tuberculosis standards, 6th ed. Ottowa: Ministry of Health; 2007. Cat no. HP40-18/2007E.
5. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-184.
6. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-636.
7. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio De Janeiro, Brazil. AIDS 2007;21:1441-1448. (Pubitemid 46988004)
8. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;CD000171.
9. World Health Organization. Global tuberculosis control: epidemiology, planning, financing: WHO Report 2009. Geneva: World Health Organization; 2009. WHO/HTM/TB/2009.411.
10. British Thoracic Society. Control and prevention of tuberculosis in the UK: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000;55:887-901.
11. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
12. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the UK: recommendations 1998. Thorax 1998;53:536-548.
13. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-722. (Pubitemid 47378885)
14. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193. (Pubitemid 19276194)
15. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes GM, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450. (Pubitemid 30151823)
16. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792. (Pubitemid 28112340)
17. Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis 2006;43:271-275. (Pubitemid 44078895)
18. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-1060.
19. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712-1717. (Pubitemid 46033423)
20. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-697.
21. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-1870. (Pubitemid 44455169)
22. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-926.
23. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005;172:1452-1456. (Pubitemid 43069820)
24. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008;178:989-993.
25. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
26. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004;72:1065-1071. (Pubitemid 38166689)
27. Zhang T, Zhang M, Grosset J, Nuermberger E. Rifapentine-based regimens cure latent tuberculosis infection (LTBI) in 2 months or less in a mouse model [abstract]. Am J Respir Crit Care Med 2009;179:A1017.
28. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003;71:1672-1679. (Pubitemid 36368696)
29. Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005;7:947-954.
30. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 2006;24:1593-1600. (Pubitemid 43238235)
31. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009;27:441-445.
32. Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med 1998;157:1436-1440. (Pubitemid 28242074)
33. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551.
34. Opie EJ, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 1927;4:1-21.
35. Brooks JV, Orme IM. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob Agents Chemother 1998;42:3047-3048.
36. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2809-2812.
37. Arriaga AK, Orozco EH, Aguilar LD, Rook GA, Hernandez PR. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002;128:229-237.
38. Rhoades ER, Frank AA, Orme IM. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 1997;78:57-66.
39. McCune RM, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J Exp Med 1956;104:737-802.
40. Lenaerts AJ, Chapman PL, Orme IM. Statistical limitations to the Cornell Model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb) 2004;84:361-364.
41. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996;40:552-555. (Pubitemid 26076566)
42. Lazarevic V, Nolt D, Flynn JL. Long-term control of mycobacterium tuberculosis infection is mediated by dynamic immune responses. J Immunol 2005;175:1107-1117. (Pubitemid 41094997)
43. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-171.
44. Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998;2:736-742. (Pubitemid 28429724)
45. Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43:2126-2130. (Pubitemid 29421188)
46. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999;67:4531-4538. (Pubitemid 29400429)
47. Brooks JV, Furney SK, Orme IM.Metronidazole therapy inmice infected with tuberculosis. Antimicrob Agents Chemother 1999;43:1285-1288.
48. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentinecontaining regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94-101. (Pubitemid 43955249)
49. Rosenthal IM, Zhang M, Grosset JH, Nuermberger EL. Rifapentinecontaining regimens cure murine tuberculosis in weeks rather than months [abstract]. Am J Respir Crit Care Med 2008;177:A789.